2 résultats
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Auteurs / Authors
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
Journal / Conference
Lancet Oncology
Année / Year
2024
PMID / session
Etude IFCT
Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7-IFCT-1402): a prospective multicentre, open-label, randomised, controlled trial
Auteurs / Authors
P. Vera, F. Le Tinier, P. Chaumet-Riffaud, E. Martin, N. Pourel, P. Boisselier, N. Salem, C. Le Pechoux, E. Giroux-Leprieur, S. Guillerm, C. Audigier Valette, D. Lerouge, C. Massabeau, P. Moisson, A. Larrouy, S. Hapdey, A. Langlais, E. Amour, G. Zalcman, P. Giraud, S. Thureau
Journal / Conference
ESMO
Année / Year
2023
PMID / session
Etude IFCT